Holger Lode Advances in Neuroblastoma Research Congress 2016

Abstracts this author is presenting:

• Interleukin-2 adds toxicity to long term infusion treatment regimen of ch14.18/CHO antibody without measurable additional activity in relapsed/refractory neuroblastoma patients. — Poster Session 1 with wine & cheese